Format

Send to

Choose Destination
Mol Oncol. 2012 Apr;6(2):237-41. doi: 10.1016/j.molonc.2012.03.001. Epub 2012 Mar 20.

Hematopoietic growth factors: personalization of risks and benefits.

Author information

1
University of Pittsburgh Cancer Institute, UPMC Cancer Centers, UPMC Cancer Pavillon, Pittsburgh, PA 15232, USA. puhallasl@upmc.edu

Abstract

A common side effect of cancer treatment is bone marrow suppression. The resulting myelosuppression and anemia can cause significant morbidity and mortality for patients. Agents such as granulocyte colony stimulating factors (GCSF) and erythropoietin stimulating agents (ESAs) may be helpful to ameliorate this depression of blood counts; however these agents have risks which also need to be carefully weighed.

PMID:
22497867
PMCID:
PMC5528376
DOI:
10.1016/j.molonc.2012.03.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center